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Abstract
Background: Differentiated thyroid cancer (DTC) survival is excellent, making recurrence a 
more clinically relevant prognosticator. We hypothesize that the new American Joint Committee 
on Cancer (AJCC) 8th edition improves upon the utility of the 7th edition in predicting the risk of 
recurrence in DTC.
Methods: A population-based retrospective review compared the risk of recurrence in patients 
with DTC according to the AJCC 7th and 8th editions using the SEER based Kentucky Cancer 
Registry from 2004–2012.
Results: A total of 3248 patients with DTC were considered disease free after treatment. Twenty 
percent of patients were down-staged from the 7th to the 8th edition. Most patients had stage I 
disease (80% in the 7th edition and 94% in the 8th edition). A total of 110 (3%) patients recurred 
after a median of 27 months. Risk of recurrence was significantly associated with stage for both 
editions (p < 0.001). In the 7th edition, there was poor differentiation between lower stages and 
better differentiation between higher stages (stage II HR 0.91, 95%CI 0.39–2.11; stage III HR 
3.72, 95%CI 2.29–6.07; stage IV HR 11.66, 95%CI 7.10–19.15; all compared with stage I). The 
8th edition better differentiated lower stages (stage II HR 4.06, 95%CI 2.38–6.93; stage III HR 
13.07, 95%CI 5.30–32.22; stage IV 11.88, 95%CI 3.76–37.59; all compared with stage I).
Conclusions: AJCC 8th edition better differentiates risk of DTC recurrence for early stages 
compared to the 7th edition. Limitations remain, however, emphasizing the importance of 
adjunctive strategies to estimate risk of recurrence.
Keywords
Differentiated Thyroid Cancer; Recurrence; AJCC 8th Edition
Correspondence Address: Tong Gan, 800 Rose Street, MN 275, Lexington, KY 40536, 859-323-6162 (Phone), 859-257-8934 (Fax), 
tong.gan@uky.edu. 
Author Disclosures: There are no disclosures for all authors
HHS Public Access
Author manuscript
Ann Surg Oncol. Author manuscript; available in PMC 2020 September 01.
Published in final edited form as:
Ann Surg Oncol. 2019 September ; 26(9): 2703–2710. doi:10.1245/s10434-019-07275-1.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Introduction:
Although thyroid cancer incidence is increasing steadily, deaths from thyroid cancer remain 
low, with a 5-year survival rate of 98.1%.1 Of these, differentiated thyroid cancer (DTC) 
comprises over 90% of all thyroid cancers.2 Lifelong surveillance for recurrence after 
treatment is required because the overwhelming majority of patients survive. For this reason, 
some even suggest that recurrence is a more appropriate prognostic end point for DTC.3 
Therefore, staging systems that stratify risk based on recurrence might be better suited to 
guide clinical management.
Many risk prediction systems exist for DTC. The American Thyroid Association (ATA) Risk 
Stratification System uses clinicopathological factors to predict risk of DTC recurrence and 
to guide adjuvant treatment strategies.2,4,5 However, pathological variables needed for the 
ATA system are often not reported and provide inadequate prognostic information. On the 
other hand, the American Joint Commission on Cancer/Union for International Cancer 
Control’s Tumor, Nodes, Metastasis (AJCC) staging system is utilized primarily to 
differentiate disease based on survival. The variables required for the AJCC system is 
required to be reported by all pathologists. Yet, the previous AJCC 7th edition is a poor 
predictor of recurrence.4 The revised 8th edition, implemented in January 2018, 
demonstrates superior survival stratification, but its ability to prognosticate recurrence is 
unknown.6–9 Major changes from the 7th edition include the increase of age cutoff from 45 
to 55, downgrading regional lymph node metastasis to stage II in older patients, and the 
removal of minimal extra-thyroidal extension (ETE) as an independent determinant of T3 
disease.10 While older age seems equivocal in determining the risk of recurrence11–15, 
regional lymph node positivity16–20 and minimal ETE21–23 uniformly increase the risk of 
recurrence.
The purpose of this study is to evaluate the AJCC 8th edition DTC TNM staging model in 
stratifying the risk of recurrence compared to the AJCC 7th edition. With the major changes 
of age, regional lymph node metastasis, and minimal ETE, we hypothesize that the 8th 
edition improves upon the ability for risk stratification of recurrence in the 7th edition.
Methods:
Registry Data:
This University of Kentucky Office of Research Integrity Institutional Review Board 
approved this study with the exempt status (Protocol ID: 43058). The Kentucky Cancer 
Registry (KCR) provided a data use agreement and access to registry data on April 27, 2018. 
The KCR is a population based central cancer registry in Kentucky established in 1990 and 
added as an expansion registry to the Surveillance, Epidemiology and End Results database 
in 2000. It has been recognized annually by the North American Association of Central 
Cancer Registries for its completeness and accuracy.24 The KCR collects the clinical and 
pathologic data necessary for TNM staging system as well as disease state and date of 
recurrence, which is lacking in many national databases.
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KCR began incorporating AJCC staging in 2004 and defined recurrence as the return of 
DTC (new disease with same the histology code as previous disease) after a disease free 
state was achieved. Coders abstracted recurrence from clinical documentation, but KCR 
does not differentiate between structural and biochemical recurrence. Disease free survival 
(DFS) was the period of time from the date when patient was diagnosed to the date of 
recurrence.
Study Population:
We identified KCR patients with DTC from 2004 – 2012 using SEER site specific code 
C739 and ICD-O-3 histology codes 8050/3 (papillary carcinoma, not otherwise specified 
[NOS]), 8260/3 (papillary adenocarcinoma, NOS), 8330/3 (follicular adenocarcinoma, 
NOS), 8331/3 (follicular adenocarcinoma, well differentiated), 8332/3 (follicular 
adenocarcinoma, trabecular), 8335/3 (follicular carcinoma, minimally invasive), 8340/3 
(papillary carcinoma, follicular variant), 8341/3 (papillary microcarcinoma), 8342/3 
(papillary carcinoma, oxyphilic cell), 8343/3 (papillary carcinoma, encapsulated), and 
8344/3 (papillary carcinoma, columnar cell). We excluded patients for whom we could not 
confidently evaluate recurrence such as those diagnosed at autopsy or on death certificate, 
those with metastatic disease, those with no or unknown operative management, those who 
were never considered disease free, and those missing recurrence data. Since we were 
comparing recurrence based on staging systems we excluded those with incomplete staging. 
We also excluded children (age less than 18) and patients with other malignancies.
Data Analysis:
Staging criteria for the 7th and 8th edition was applied separately to the same population 
based on the AJCC criteria to create two groups. The Kaplan Meier method estimated DFS. 
Log rank tests compared DFS by stage. Cox regression identified risk factors for recurrence 
to determine which components of the 8th edition influenced accurate prediction of 
recurrence. Selective multivariate analyses included age, sex and all factors significantly 
associated with recurrence from the univariate analyses. Cox proportional hazard regression 
provided hazard ratios (HR) and confidence intervals by stage. An α of 0.05 defined 
statistical significance. We used SAS/STAT version 9.4 (Cary, NC) for all analyses.
Results:
Patient characteristics:
There were 4676 patients diagnosed with DTC in Kentucky from 2004 to 2012. Of these, 
3248 formed the final study cohort. A total of 1428 patients were excluded for the following 
reasons: age less than 18 (n = 51), M1 disease (n = 52), never considered disease free (n = 
469), other cancer diagnosis (n = 607), diagnosis on autopsy or death (n = 3), missing 
recurrence data (n = 323), none or unknown surgical management (n = 179), unknown or 
incomplete staging (n = 219). The median age was 48 years and the majority were female (n 
= 2591, 80%) and Caucasian (n = 3031, 93%; Table 1). The median follow-up time for all 
patients was 88.9 months (IQR 65.2 – 118.1 months). There were 110 (3%) patients whose 
disease recurred by the end of the study period. The median time to first recurrence was 27.5 
months (IQR 13.6 – 53.4 months).
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According to AJCC staging for either edition, most patients had stage I disease (80% in the 
7th edition and 94% in the 8th edition), and almost all patients had either stage I or II disease 
(89% in the 7th edition and 99% in the 8th edition). In comparing the two cohorts, we 
identified that 20% of patients were down-staged from the 7th edition to the 8th and no 
patients were upstaged (Figure 1). In fact, all patients staged II - IV were down-staged at 
least one stage from the 7th to the 8th edition.
Disease Free Survival:
Both the AJCC 7th and 8th edition staging models significantly stratified the risk of 
recurrence (Figure 2). When comparing between editions, DFS was similar for stage I 
patients regardless of the particular edition (Table 2a). This finding demonstrated the cases 
that were down-staged to stage I in the 8th edition represented low risk disease. Stage II and 
III disease conferred a greater risk of recurrence in the 8th compared to the 7th edition, but 
stage IV disease did not.
When comparing between stages within each edition, the 7th edition had poor differentiation 
of lower stages and better differentiation of higher stages (Table 2b). Risk of recurrence was 
not different between stage I and II in the 7th edition, but increased stage from II to III and 
III to IV was associated with a higher risk of recurrence. In contrast, the 8th edition better 
differentiated the risk of recurrence at lower stages. Stage II had significantly higher risk of 
recurrence than stage I, but stage IV disease was not associated with a greater risk of 
recurrence compared to stage II or III disease.
Patient Characteristics Relating to Recurrence:
We performed univariate and multivariate cox regression to identify the components of the 
8th edition staging system that impacted its ability to stratify the risk of recurrence (Table 3). 
Our multivariate model included age (55-year cut-off used in the 8th edition), sex, and any 
significant variables from the univariate analyses. After adjusting for sex, disease 
characteristics (focality, ETE, T stage, nodal status), and treatment variation (extent of 
surgery, adjuvant radiation), higher recurrence rates were independently associated with age 
55 and older, higher T stage (8th edition), and lymph node positivity. Interestingly, ETE, 
focality, surgical extent and adjuvant therapy were no longer associated with recurrence.
Discussion:
While the AJCC 7th edition TNM staging system effectively predicted survival for patients 
with DTC, it poorly stratified the risk of recurrence.2,5 We compared the ability of the new 
AJCC 8th edition to prognosticate the risk of recurrence to that of the 7th edition using 
population based data from the state of Kentucky. Stage escalation conferred significantly 
higher risk of recurrence according to each edition overall, but the 8th edition provided better 
risk differentiation at lower stages than the 7th edition. Considering stage I and II disease 
accounts for the overwhelming majority of patients with DTC, the ability to distinguish the 
risk of recurrence between lower stages is paramount. The risk of recurrence was similar 
between stage I and II for the 7th edition, but significantly higher for stage II compared with 
stage I in the 8th edition. This demonstrates that the 8th edition more appropriately places 
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lower risk patients into stage I and higher risk patients into stage II when compared to the 7th 
edition. Therefore, the 8th edition appears more clinically useful in its ability to stratify 
patients according to the risk of DTC recurrence, even though it did not stratify the risk of 
recurrence of higher stages as well as the previous edition.
The 8th edition increased the staging age cutoff from 45 to 55, condensed lymph node 
positivity to stage II in older patients, and removed minimal ETE as a determinate of T stage 
in older patients.10 Even though our study excluded patients with metastatic disease for the 
purpose of accurately detecting recurrence, the resulting down-staging (20%) in the current 
study is comparable to prior studies (12%−27%).6,7,12,25
Interestingly, age 55 or greater conferred a higher risk of recurrence in the current study after 
adjusting for other factors predictive of recurrence. Historically, age 55 years or greater 
reliably indicated worse survival for patients with DTC, but its impact on recurrence have 
been unclear.12 Cho et al.11 demonstrated age greater than 62.5 is associated with 
significantly higher recurrence risk in DTC. However, other investigations failed to 
demonstrate an association between older age and recurrence.13–15 In fact, a meta-analysis 
demonstrated that age less than 45 was highly associated with recurrence.26 Nevertheless, 
our data indicate that increasing the age cut-off to 55 appropriately allocates higher risk of 
recurrence based on age to higher staged disease.
Positive lymph nodes conferred worse DFS in the current study, but the overall impact of 
nodal status on risk stratification according to the 8th edition is unclear. Nearly two-thirds of 
the study cohort was younger than 55 years and are classified with stage I disease regardless 
of nodal status. For the third of patients who were 55 years or older, those with positive 
nodes in the absence of T4 disease were down-staged to stage II from stage III. This change 
may account for the increased risk of recurrence for stage II patients according to the 8th 
edition compared to that for stage II in the 7th edition. Although other literature indicates 
that regional lymph node metastasis may have minor impacts on survival, node positivity 
consistently incurs a higher risk of recurrence.10,13,16–20
Higher T stage, now based entirely upon tumor size and gross local invasion, correlates with 
higher recurrence rates in our current study. In the previous edition, minimal ETE 
automatically equated to T3 disease. Similar to node positivity, minimal ETE is associated 
with higher recurrence rates compared to no ETE, but does not correlate with survival.21–23 
In a metanalysis by Diker-Cohen et al,23 minimal ETE was associated with increased 
recurrence in those without lymph node disease. Yet, due to its low impact on survival, the 
AJCC removed minimal ETE from the 8th edition staging criteria.10 Interestingly, our results 
demonstrate after adjusting for age, sex, T stage and extent of surgery, ETE was no longer a 
significant predictor of recurrence. Despite the change which moved tumors less than 4cm 
from T3 classification to T1 or T2, T3 disease still confers at least twice the risk of 
recurrence as T1 in the 8th edition.
This study represents a large population-based comparative cohort, but it does have some 
limitations. Kentucky captures both rural and urban populations and may be generalizable to 
the greater United States, but systematic differences in disease or treatment in Kentucky is 
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possible. We excluded patients who had metastatic disease, as these patients were never 
disease free to have a recurrence. Although our stage IV group likely does not have the same 
survival as the general population which includes metastatic disease, we would expect the 
DFS to be similar as it cannot be measured in those with metastatic disease. Further, the 
large confidence interval is likely due to the small sample size of the remaining stage III and 
IV 8th edition population. Although the KCR is quite accurate and captures recurrence, 
patients who move outside of Kentucky would be lost to follow-up. However, if patients 
remain in Kentucky, even if they change physicians or treatment locations, their data would 
not be lost. Excluding patients without recurrence data narrowed our sample population, but 
it also allowed us to confidently identify groups with and without recurrence. Additionally, 
any unknown selection bias resulting from the identification of our sample population would 
minimally affect our results, because we compared staging systems using the same 
population. Another limitation involves the follow-up time. Although, the median follow-up 
time was relatively long at 91 months, late recurrences are possible. However, since most 
DTC recurrence occurs in the first 3–4 years, the shorter follow-up time may have minimal 
effects on this study.27,28 Lastly, there are limitations that are inherent to the use of large 
databases. These include inaccurate and incomplete data entered by the registrar. However, 
this is less likely to occur with KCR due to its excellent record for its completeness and 
accuracy by the North American Association of Central Cancer Registries.24
Conclusions:
This population based study evaluated the ability of the revised AJCC 8th edition to stratify 
DTC recurrence compared to the previous edition. The ability of the 8th edition to predict 
recurrence correlates with the substantial downstaging of patients from the 7th edition. The 
8th edition is more clinically useful because it better differentiates the risk of recurrence 
between lower stage disease where the majority of patients fall. Despite this improvement, 
supplemental risk stratification systems remain important to guide surveillance and 
adjunctive therapies.
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Synopsis:
The 8th edition’s ability to predict risk of recurrence in Differentiated Thyroid Cancer 
was evaluated. The 8th edition differentiates lower staged disease better than the 7th, 
providing a more useful clinical tool for the majority of patients.
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Figure 1. The Restaging and Migration of the Study Population From the AJCC 7th Edition to 
the 8th Edition.
The study population was previously staged based on the 7th edition criteria. Utilizing the 
major changes to the revised 8th edition, an algorithm was generated that allowed restaging 
according to the 8th edition. A large proportion of the stage I patients remained stage I all 
other stages were down-staged, no patients remained in the same stage nor were upstaged.
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Figure 2. Comparison of Disease Free Survival between the AJCC 7th and 8th Editions.
Disease free survival was plotted by the Kaplan Meier method comparing Stage I - IV in 
both editions. Both comparisons were statistically significant.
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Table 1.
Study Population Demographics and Clinicopathological Factors.
Patient
Characteristics
KYDTC
2004–2012
(n = 3248)
Age
 <45 1342 (41 %)
 45–54 818 (25%)
 55–74 970 (30%)
 75+ 118 (4%)
Sex
 Female 2591 (80%)
 Male 657 (20%)
Race
 White 3031 (93%)
 Black 164 (5%)
 Other 34 (2%)
Insurance
 Not Insured 107 (3%)
 Insured 3093 (95%)
 Unknown 48 (2%)
Histology
 Papillary Cancer 3056 (94%)
 Follicular Cancer 192 (6%)
Focality
 Solitary 2019 (62%)
 Multifocal 1157 (36%)
Unknown 72 (2%)
Extrathyroidal Extension
 Absent 2928 (90%)
 Present 320 (10%)
Surgical Approach
 Lobectomy 686 (21%)
 Total Thyroidectomy 2523 (78%)
 Thyroidectomy, NOS 39 (1 %)
Adjuvant Radiation
 External Beam 14 (<1%)
 Radioisotope 1603 (49%)
 None 1432 (44%)
 Other 199 (6%)
T Stagea
 0 7 (<1 %)
 1 1826 (56%)
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Patient
Characteristics
KYDTC
2004–2012
(n = 3248)
 2 487 (15%)
 3 357 (11%)
 4 47 (2%)
 Unknown 512 (16%)
aAccording to the AJCC 8th Edition. KY Kentucky, DTC Differentiated Thyroid Cancer, NOS Not Otherwise Specified
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Table 2
Comparison of Recurrence Risk Between the AJCC 7th and 8th Editions.
a) Comparison of 5 and 10 year DFS between the two editions. b) Comparison of the Risk of Recurrence 
Between Individual Stages in the AJCC 7th and 8th Editions.
a) Stage Year AJCC 7th Ed AJCC 8th Ed p-value
DFS 95% CI DFS 95% CI
I 5 98.0% (97.4–98.5%) 97.7% (97.1–98.2%) NS
II 99.3% (97.1–99.8%) 90.1% (84.7–94.4%) < 0.001
III 92.0% (88.1–94.7%) 79.4% (48.8–92.9%) NS
IVa 84.5% (74.7–90.7%) 90.1% (50.8–98.7%) NS
I 10 97.5% (96.8–98.1%) 96.8% (96.1–97.5%) NS
II 96.6% (91.8–98.5%) 84.1% (71.2–91.5%) 0.018
III 90.4% (84.8–94.0%) 57.8% (23.9–81.0%) 0.037
IVa 68.1% (54.0–78.6%) 58.9% (17.1–85.4%) NS
b) Stage AJCC 7th Edition AJCC 8th Edition
HR 95% CI p-value HR 95% CI p-value
I Ref - - Ref - -
II 0.91 (0.39–2.11) 0.827 4.06 (2.38–6.93) < 0.001
III 3.72 (2.29–6.07) < 0.001 13.07 (5.30–32.22) < 0.001
IVa 11.66 (7.10–19.15) < 0.001 11.88 (3.76–37.59) < 0.001
aStage IV disease excludes all metastatic disease. DFS Disease Free Survival, 95%CI 95% Confidence Interval, HR Hazard Ratio.
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Table 3.
Univariate and Multivariate Analysis of Predictors of Recurrence.
Independent Variable Univariate Analysis Multivariate Analysis
HR 95% CI p value HR 95% CI p value
Age ≥ 55 vs < 55 1.24 (0.84–1.83) NS 1.68 (1.12–2.51) 0.011
Female vs Male 0.58 (0.39–0.87) 0.009 0.81 (0.53–1.23) NS
Race
 Black vs White 1.62 (0.83–3.25) NS - - -
 Other vs White 2.02 (0.50–8.18) NS - - -
Insurance Status
 Insured vs None 0.57 (0.25–1.29) NS - - -
 Unknown vs None 0.32 (0.04–2.68) NS - - -
Tumor (T) Stagea
 T2 vs T1 1.57 (0.95–2.60) NS 1.14 (0.68–1.91) NS
 T3 vs T1 3.87 (2.42–6.20) < 0.001 2.04 (1.12–3.69) 0.019
 T4 vs T1 8.12 (4.32–15.27) < 0.001 2.72 (1.16–6.36) 0.0213
ETE vs no ETE 4.38 (2.92–6.57) <0.001 1.06 (0.57–1.96) NS
Multifocal vs Solitary 2.12 (1.45–3.09) < 0.001 1.38 (0.93–2.05) NS
Lobectomy vs Total 0.48 (0.27–0.86) 0.013 0.98 (0.53–1.82) NS
LN Examination
 Pos vs Neg 5.10 (3.20–8.14) < 0.001 3.39 (2.02–5.68) < 0.001
 None Examined vs Neg 0.67 (0.41–1.11) NS 0.68 (0.41–1.14) NS
Adjuvant Therapy
 XRT vs None 6.54 (2.51–17.09) < 0.001 1.63 (0.57–4.67) NS
 I131 vs None 2.84 (1.81–4.46) < 0.001 1.55 (0.93–2.58) NS
aAccording to the AJCC 8th Edition. ETE extrathyroidal extension, LN Lymph node, XRT External Beam Radiation, I131 Radioactive iodine.
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